The global Heparin Market size was estimated at USD 8.78 billion in 2020 and is projected to expand at a CAGR of 2.4%.
Market Players who gives major contribution in heparin market includes Sansofi, Leo Pharma, Pfizer, GlaxosmitheKline, Baxter Healthcare, Fresnius Kabi AG and aspen Holdings.
India is considering allowing import of raw material for manufacturing crude heparin, an anticoagulant being used for treatment of Covid-19 patients, a move aimed at reducing dependence on china. B. Braun Medical Inc. announced the launch of its Heparin Sodium Injection, USP - the first Heparin 5,000 USP Unit / 0.5 mL prefilled syringe with attached safety needle for subcutaneous and intravenous use in the United States. Heparin Sodium Injection, USP is indicated for: prophylaxis and treatment of venous thrombosis and pulmonary embolism, prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease, atrial fibrillation with embolization, treatment of acute and chronic consumptive coagulopathies. India, a global hub for generic drugs, has launched a new scheme to boost production of active However, API prices of common antibiotics like norfloxacin and ciprofloxacin, as well as paracetamol and some vitamins have shot up.
Based on type, the market is segmented into low molecular weight, ultra-low molecular weight, and unfractionated heparin. Based on the application, the market has been categorized into venous thromboembolism, atrial fibrillation, renal impairment, and coronary artery disease. Based On region it has been segmented into North America, Europe, Asia-Pacific and Row. The Asia-Pacific region is expected to be the largest geographic segment in the market, growing at a CAGR ranging from 5% to 1.0% during the forecast period.